Table 5.
Performance and clinical utility of the prediction model: numbers of avoided TBx sessions, low-risk PCa diagnoses, and missed csPCa using a risk threshold range of 2% to 10%.
| Threshold | TBx Sessions | ISUP Grade 1 PCa | ISUP Grade ≥2 PCa |
|---|---|---|---|
| Risk of csPCa | Avoided (n, %) | Not Detected (n, %) | Missed Diagnosis (n, %) |
| Monitor all patients | 292 (100%) | 53 (100%) | 39 (100%) |
| Biopsy all patients | 0 (0%) | 0 (0%) | 0 (0%) |
| ≥2% | 10 (3%) | 1 (2%) | 0 (0%) |
| ≥3% | 30 (10%) | 2 (4%) | 0 (0%) |
| ≥4% | 47 (16%) | 4 (8%) | 1 (3%) |
| ≥5% | 65 (23%) | 7 (13%) | 1 (3%) |
| ≥6% | 84 (30%) | 9 (17%) | 2 (5%) |
| ≥7% | 97 (34%) | 12 (23%) | 2 (5%) |
| ≥8% | 119 (42%) | 16 (30%) | 3 (8%) |
| ≥9% | 137 (48%) | 20 (38%) | 3 (8%) |
| ≥10% | 150 (53%) | 22 (42%) | 4 (10%) |
CsPCa: clinically significant prostate cancer; TBx: targeted biopsy; ISUP: International Society of Urological Pathology; PCa: prostate cancer.